Etanercept is a recombinant, fully human, soluble, TNF- fusion protein. It modulates the activity of the proinflammatory cytokine TNF- by competitively binding to both cell-surface and soluble TNF-a, preventing the interaction of TNF- with endogenous receptors located on the cell surface. Unlike TNF-a monoclonal antibodies, when this soluble fusion protein binds to cell-bound TNF-a, it does not induce complement-mediated cell lysis.
The pharmacokinetics of etanercept is similar across different adult populations, including women and the elderly, and across several inflammatory disease states. In addition, pharmacokinetic parameters in children receiving a weight-based dose are similar to those in adults. Etanercept has shown clinical efficacy in the treatment of rheumatoid arthritis, active polyarticular-course juvenile chronic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Moreover, etanercept has demonstrated a similarly favorable safety profile across all indications.
Acknowledgement. The author would like to thank Rick Davis, MS, RPh, for his significant contribution to the writing of this chapter.
Was this article helpful?